Hemoccult® Fecal Occult Blood Tests

		It's E.A.S.Y. with Hemoccult^® Products
		Hemoccult - Our name is synonymous with fecal occult blood tests.

Hemoccult Products

The E.A.S.Y Hemoccult tests are

E ffective- Hemoccult has been clinically proven to significantly lower the burden of colorectal cancer by reducing incidence and mortality.^1,2

A ccessible- Designed to screen large populations of people. Cost effective and samples can be collected at the patient’s home.

S afe- Non- Invasive.

Y early- Recognized as an effective CRC screening tool when performed on a yearly basis

They are a rapid, convenient and qualitative methods for detecting fecal occult blood which may be indicative of gastrointestinal disease.

The Hemoccult test is recommended for:

	Professional use as a diagnostic aid during routine physical examinations.
	Hospital patients to monitor for gastrointestinal bleeding, in patients with iron deficiency anemia or recuperating from surgery, peptic ulcer, ulcerative colitis and other conditions.
	Screening programs for colorectal cancer when the Patient Instructions are closely followed.^3,4

Hemoccult has:

	Over 300 clinical studies of support
	Built-in Performance Monitor
	14 day on-slide sample stability
	Comprehensive patient educational support
	Clinically proven results

Product Effectiveness

Prospective, randomized controlled clinical trials extending for up to 18 years have demonstrated that the Hemoccult products are effective in detecting occult blood in stool as an early indication of colorectal cancer.

In clinical trials that enrolled over 339,000 individuals, mortality from colorectal cancer was reduced up to 33% when fecal occult blood tests were performed annually^5-7 and 15-21% when performed biennially.⁸

The program sensitivity for detecting colorectal cancer when Hemoccult was performed annually was 90%.^9,10

ICT Components:

The Hemoccult ICT test consists of three main components:

1.	Hemoccult ICT Collection Cards
2.	Hemoccult ICT Test Cards
3.	Hemoccult ICT Buffer

	Separate Collection Cards and Test Devices
	Having separate Collection Cards and Test Devices minimizes the financial risk of patients not returning Collection Cards. The expense of providing Collection Card for CRC screening is very similar to the traditional Hemoccult guaiac product.

Guaiac Components:

The Hemoccult test consists of two main components:

1.	Hemoccult or Hemoccult II Slides (Test Cards)
2.	Hemoccult Developer, a stabilized peroxide and 75% denatured ethyl

Hemoccult Single Slides are convenient for use when single fecal specimens are collected for routine in-office gastrointestinal screening.

Hemoccult II Slides are designed so patients can collect serial specimens at home from bowel movements over three days.

After the patient prepares the Hemoccult II test, it may be returned in person or by mail (using the Hemoccult Mailing Pouch) to the laboratory, hospital or medical office for developing and interpretation.

Polyps and cancer may bleed intermittently. Hemoccult II triple slides are designed so patients collect serial specimens over three days. This increases the probability of detecting hidden blood from polyps and cancer.

	Hemoccult Product Links
	Product Instructions Configurations Material Safety Data Sheets Downloadable Sales Tools

References:

1. C Mandel, Jack S., et al.: “The effect of fecal occult-blood screening on the incidence of colorectal cancer,” NEJM. 343:1603-1607, 2000.

2. Pignone M, Rich M, Teutsch SM, et al.: “Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S.
Preventative Services Task Force.” Ann Int Med 2002;137:132-141.

3. Winawer, S.J., et al.: "Colorectal cancer screening: Clinical guidelines and rationale," Gastroenterol. 112:594-642, 1997.

4. Winawer, S.J., et al.: "Prevention of colorectal cancer: Guidelines based on new data," WHO Bulletin OMS. 73:7-10, 1995.

5. Hardcastle, J.D., et al.: "Randomised controlled trial of faecal-occult-blood screening for colorectal cancer," Lancet. 348:1471-1477, 1996.

6. Kronborg, O., et al.: "Randomised study of screening for colorectal cancer with faecal-occult-blood test," Lancet. 348:1467-1471, 1996.

7. Mandel, J.S., et al.:"Reducing mortality from colorectal cancer by screening for fecal occult blood," N Eng J Med. 328:1365-1371, 1993.

8. Mandel, J.S., et al.: "Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood," J Natl Cancer Inst. 91:434-437, 1999.

9. Ederer, F., et al.: "Fecal occult blood screening in the Minnesota Study: Role of chance detection of lesions," J Natl Cancer Inst. 89:1423-1428, 1997.

10. Church, T.R., et al.: "Fecal occult blood screening in the Minnesota Study: Sensitivity of the screening test," J Natl Cancer Inst. 91:1440-1448, 1997.